Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Nutr Metab Cardiovasc Dis ; 9(6): 304-11, 1999 Dec.
Article in English | MEDLINE | ID: mdl-10765523

ABSTRACT

The Atherosclerosis and Dysmetabolic Disorders Study Group, headed by Prof. Rodolfo Paoletti, decided in 1994 to compose a committee of experts to formulate a clear description of familial combined hyperlipoproteinemia (FCH), a disorder illustrated in the literature, but still unknown to most physicians in spite of its severity and relative diffusion. The Committee consists of experts from the Lipid Clinics of the Universities of Ancona, Bari, Bologna, Ferrara, Genoa, Milan, Naples, Padua, Palermo, Perugia, Rome, Sassari, Turin, Verona and Venice. It has held several meetings coordinated by the national secretary at the "Giancarlo Descovich" Atherosclerosis Centre of the University of Bologna. This paper summarizes its conclusions.


Subject(s)
Hyperlipidemia, Familial Combined/diagnosis , Humans , Hyperlipidemia, Familial Combined/epidemiology , Hyperlipidemia, Familial Combined/genetics , Hyperlipidemia, Familial Combined/metabolism , Phenotype , Prevalence
2.
J Int Med Res ; 24(5): 389-406, 1996.
Article in English | MEDLINE | ID: mdl-8895043

ABSTRACT

The aim was to look at the effect of sulodexide in diabetic and non-diabetic patients with peripheral occlusive arterial disease (POAD), by verifying, through meta-analysis of Italian data, if the drug affects the clinical course of claudication or the main risk factors for POAD. Sulodexide increases the pain-free walking distance (benefit 36% vs controls, P < 0.001). The meta-analysis confirmed the effectiveness of sulodexide in improving claudication (lower limit of the 95% CI for overall odds ratio always > 1). There was a marked effect in lowering triglycerides (overall -28%, P = 0.0015), fibrinogen (-13%, P < 0.0001) and plasma and serum viscosities, and in increasing high-density-lipoprotein cholesterol (24.4%, P = 0.0007). The medium-term administration of sulodexide has a therapeutic effect on claudication of diabetic and/or hyperlipidaemic patients suffering from POAD stages- and also counteracts several POAD risk factors. Long-term use of sulodexide appears to be well tolerated. The treatment has a low daily cost; therefore, it has a favourable cost-benefit ratio, in view of the high general costs associated with global POAD care, particularly in diabetic patients.


Subject(s)
Arterial Occlusive Diseases/drug therapy , Glycosaminoglycans/therapeutic use , Hypolipidemic Agents/therapeutic use , Adult , Aged , Arterial Occlusive Diseases/blood , Blood Viscosity/drug effects , Diabetic Angiopathies/blood , Diabetic Angiopathies/drug therapy , Exercise Test , Fibrinogen/metabolism , Humans , Intermittent Claudication/blood , Intermittent Claudication/drug therapy , Italy , Middle Aged , Triglycerides/blood
SELECTION OF CITATIONS
SEARCH DETAIL
...